Provectus Announces Presentation of Updated Data from Metastatic Uveal Melanoma Cohort of Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
June 01, 2020 09:00 ET
|
Provectus Biopharmaceuticals Inc.
Treatment refractory, immunologically cold, hepatic tumor type37% reduction and 83% stabilization of treated disease (2D-EASL)Overall survival of 11 months for checkpoint inhibition-naïve patients;...
Provectus Announces Publication of Updated Data from Metastatic Neuroendocrine Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
June 01, 2020 07:00 ET
|
Provectus Biopharmaceuticals Inc.
Treatment refractory, immunologically cold, hepatic tumor type50% reduction of treated disease; 83% stabilization of overall patient disease (RECIST)Median progression-free survival not reached (by CT...
Provectus Announces Acceptance of PV-10® Liver Cancer Abstracts at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
April 29, 2020 16:30 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 29, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that abstracts about and data from our clinical trials of investigational autolytic cancer...